We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
US analyst rating / recommendation change.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
Consensus vs. actual, and revenue trend
Rating & price-target changes
Stored first · Google News · Yahoo Finance (English)
Enterprise value to EBITDA forward of Champions Oncology, Inc. – SWB:2I3 - TradingView
Enterprise value to EBITDA forward of Champions Oncology, Inc. – SWB:2I3 TradingView
Champions Oncology (CSBR) Declines Sharply, Approaches Key Support at $5.38 - Volatility Stop - dars.gov.et
Champions Oncology (CSBR) Declines Sharply, Approaches Key Support at $5.38 - Volatility Stop dars.gov.et
Enterprise value to revenue forward of Champions Oncology, Inc. – NASDAQ:CSBR - TradingView
Enterprise value to revenue forward of Champions Oncology, Inc. – NASDAQ:CSBR TradingView
Price to sales forward of Champions Oncology, Inc. – NASDAQ:CSBR - TradingView
Price to sales forward of Champions Oncology, Inc. – NASDAQ:CSBR TradingView
Price to book forward of Champions Oncology, Inc. – FWB:2I3 - TradingView
Price to book forward of Champions Oncology, Inc. – FWB:2I3 TradingView
Champions Oncology, Inc. Actuals & Estimates (NASDAQ:CSBR) - TradingView
Champions Oncology, Inc. Actuals & Estimates (NASDAQ:CSBR) TradingView
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 03. 12. | After market close (AMC) | — | — | — | — | — | Scheduled |
| FY2026 Q3 | 2025. 01. 31. | Time TBD | — | $0.46 | — | — | $44.59M | Reported |
| FY2026 Q2 | 2024. 10. 31. | Time TBD | — | $0.15 | — | — | $27.55M | Reported |
| FY2026 Q1 | 2024. 07. 31. | Time TBD | — | $0.09 | — | — | $14.06M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2025. 03. 12. | Craig-Hallum | — | Maintain | Buy → Buy | — | Craig-Hallum: Buy |
| 2024. 12. 13. | Craig-Hallum | — | Maintain | Buy → Buy | — | Craig-Hallum: Buy |
| 2024. 09. 12. | Craig-Hallum | — | Upgrade | Hold → Buy | — | Craig-Hallum: Hold → Buy |
| 2024. 03. 13. | Craig-Hallum | — | Downgrade | Buy → Hold | — | Craig-Hallum: Buy → Hold |
| 2023. 09. 23. | Roth MKM | — | Maintain | Buy → Buy | — | Roth MKM: Buy |
| 2021. 03. 15. | Roth Capital | — | Maintain | — → Buy | — | Roth Capital: Buy |
As of FY2026Q3 · Source: SEC/DART + price data
No holdings data to show.